Melanotan II (MT2) 10mg
I. Basic Information
Name: Melanotan II (MT-II)
Purpose and Background: To darken skin color by stimulating melanin production.
Regulatory Status: Not FDA approved; discussed only in research/over-the-counter settings.
Common Method of Use: Subcutaneous injection (SubQ)
II. Usage Phase Division (Logical Framework)
Loading Phase
Purpose: To allow the body to gradually adapt and reduce the risk of adverse reactions.
Characteristics:
Start with a low dose
Gradually increase the dose every 1–2 weeks
Usually once daily
Common Approach (not a Recommendation):
Initial Phase: Low dose (e.g., 250 mcg)
Middle Phase: Medium dose (e.g., 500 mcg)
Late Phase: Higher dose (e.g., 1 mg)
Intensive Phase (Optional)
Purpose: To promote faster pigmentation
Characteristics:
Faster dose escalation
Higher incidence of side effects
More suitable for experienced users
Maintenance Phase
Purpose: To maintain the achieved skin tone
Characteristics:
No longer used daily
Switch to 1–2 times per week
Dosage is usually lower than or equal to that of the Intensive Phase
III. Common Dosage Ranges
| Phase | Typical Dose Range (commonly cited) | Frequency |
|---|---|---|
| Loading | 250–500 mcg | Daily |
| Advanced | 500–1000 mcg | Daily |
| Maintenance | 500–1000 mcg | 1–2× per week |
Individual tolerance varies significantly. Higher doses are not inherently safer or more effective.
